PPM1G

Summary

PPM1G (protein phosphatase, Mg2+/Mn2+ dependent 1G, HGNC:9278) is a protein-coding gene on chromosome 2p23.3, encoding Protein phosphatase 1G (O15355). It is a selective cancer dependency (DepMap: 12.8% of cell lines).

The protein encoded by this gene is a member of the PP2C family of Ser/Thr protein phosphatases. PP2C family members are known to be negative regulators of cell stress response pathways. This phosphatase is found to be responsible for the dephosphorylation of Pre-mRNA splicing factors, which is important for the formation of functional spliceosome. Studies of a similar gene in mice suggested a role of this phosphatase in regulating cell cycle progression.

Source: NCBI Gene 5496 — RefSeq curated summary.

At a glance

• GWAS associations: 8
• Clinical variants (ClinVar): 50 total
• Druggable target: yes — 1 molecules with ChEMBL bioactivity
• Cancer dependency (DepMap): dependent in 12.8% of screened cell lines
• MANE Select transcript: NM_177983

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:9278
Approved symbol	PPM1G
Name	protein phosphatase, Mg2+/Mn2+ dependent 1G
Location	2p23.3
Locus type	gene with protein product
Status	Approved
Aliases	PP2CG, PP2Cgamma
Ensembl gene	ENSG00000115241
Ensembl biotype	protein_coding
OMIM	605119
Entrez	5496

Gene structure

Transcript identifiers

Ensembl transcripts: 7 — 5 protein_coding, 2 retained_intron

ENST00000344034, ENST00000472077, ENST00000484925, ENST00000893256, ENST00000893257, ENST00000893258, ENST00000948123

RefSeq mRNA: 1 — MANE Select: NM_177983 NM_177983

CCDS: CCDS1752

Canonical transcript exons

ENST00000344034 — 10 exons

Exon	Start	End
ENSE00000734804	27384673	27385088
ENSE00000734808	27386194	27386279
ENSE00001036142	27387089	27387158
ENSE00001166701	27385747	27385879
ENSE00001816184	27381199	27381805
ENSE00001830933	27409303	27409591
ENSE00003589848	27382476	27382605
ENSE00003601752	27383952	27384092
ENSE00003652107	27383366	27383600
ENSE00003680244	27382126	27382228

Expression profiles

Bgee: expression breadth ubiquitous, 282 present calls, max score 99.21.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 101.1211 / max 744.0386, expressed in 1828 samples.

FANTOM5 promoters (5 alternative TSS)

Promoter ID	TPM avg	Samples expressed
27501	99.0036	1828
27495	1.0962	677
27500	0.4853	223
27494	0.3938	169
27499	0.1421	33

Top tissues by expression

295 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
left testis	UBERON:0004533	99.21	gold quality
right testis	UBERON:0004534	99.17	gold quality
testis	UBERON:0000473	97.57	gold quality
ganglionic eminence	UBERON:0004023	96.95	gold quality
cortical plate	UBERON:0005343	96.31	gold quality
sperm	CL:0000019	96.29	gold quality
ventricular zone	UBERON:0003053	96.27	gold quality
male germ cell	CL:0000015	96.09	gold quality
islet of Langerhans	UBERON:0000006	95.82	gold quality
mucosa of transverse colon	UBERON:0004991	95.77	gold quality
gastrocnemius	UBERON:0001388	95.58	gold quality
endometrium epithelium	UBERON:0004811	95.45	gold quality
granulocyte	CL:0000094	95.37	gold quality
muscle of leg	UBERON:0001383	95.13	gold quality
stromal cell of endometrium	CL:0002255	95.09	gold quality
rectum	UBERON:0001052	94.90	gold quality
embryo	UBERON:0000922	94.70	gold quality
esophagus mucosa	UBERON:0002469	94.52	gold quality
body of stomach	UBERON:0001161	94.43	gold quality
hindlimb stylopod muscle	UBERON:0004252	94.31	gold quality
left adrenal gland	UBERON:0001234	94.30	gold quality
right adrenal gland	UBERON:0001233	94.27	gold quality
adenohypophysis	UBERON:0002196	94.27	gold quality
esophagus	UBERON:0001043	94.26	gold quality
olfactory segment of nasal mucosa	UBERON:0005386	94.19	gold quality
lower esophagus muscularis layer	UBERON:0035833	94.13	gold quality
transverse colon	UBERON:0001157	94.12	gold quality
popliteal artery	UBERON:0002250	94.12	gold quality
tibial artery	UBERON:0007610	94.12	gold quality
lower esophagus	UBERON:0013473	94.12	gold quality

Single-cell (SCXA)

Detected in 7 experiment(s), a significant marker in 5.

Experiment	Marker?	Max mean expression
E-GEOD-134144	yes	32.26
E-CURD-112	yes	9.71
E-ANND-3	yes	9.14
E-MTAB-10042	yes	5.20
E-CURD-88	yes	4.24
E-MTAB-7303	no	338.58
E-CURD-120	no	30.69

Regulation

Is transcription factor: no

Functional genomics

DepMap (CRISPR cell-line fitness): dependent in 12.8% of screened cell lines.

Literature-anchored findings (GeneRIF, showing 22)

• The degradation of p21(WAF1/CIP1) induced by PP2Cgamma was mediated in a proteasome-dependent manner. (PMID:17054950)
• Protein phosphatase 2C gamma mediates histone dephosphorylation/exchange in response to DNA damage or checkpoint recovery in higher eukaryotes. (PMID:17074886)
• PP2Cgamma modulates alternative splicing of specific pre-mRNAs coregulated by YB-1. (PMID:17572683)
• an interplay between PPM1G and unrip determine compartment-specific phosphorylation patterns, localization, and function of the SMN complex (PMID:17984321)
• PP2Cgamma is a novel regulator of p21(Cip1/WAF1) protein stability via the Akt signaling pathway. (PMID:19538940)
• ATM-dependent downregulation of USP7/HAUSP by PPM1G activates p53 response to DNA damage (PMID:22361354)
• study has identified protein phosphatase PPM1G as a novel regulator of cap-dependent protein translation by negatively controlling the phosphorylation of 4E-BP1. (PMID:23814053)
• PPM1G dephosphorylates the P-TEFb kinase T loop to disassemble the 7SK snRNP. (PMID:24316072)
• PPM1G inactivates monomeric WWP2 and promotes the assembly of WWP2-WWP1 heterodimeric complex. (PMID:25071155)
• Hypermethylation in the 3’-protein-phosphatase-1G (PPM1G) gene locus was associated with alcohol use disorder. (PMID:25982659)
• PPM1G phosphatase directly binds 7SK RNA and the kinase inhibitor Hexim1 once P-TEFb has been released from the 7SK snRNP. (PMID:26324325)
• a new holoenzyme with PPM1G-B56delta as integral components, in which the regulatory subunit provides accessibility to distinct substrates for the phosphatase by defining its cellular localization, is reported. (PMID:31432583)
• Association of PPM1G methylation with risk-taking in alcohol use disorder. (PMID:32218500)
• Proteomics reveals protein phosphatase 1gamma as a biomarker associated with Hippo signal pathway in glioma. (PMID:32919304)
• The ARF tumor suppressor targets PPM1G/PP2Cgamma to counteract NF-kappaB transcription tuning cell survival and the inflammatory response. (PMID:33288725)
• Prognostic and immunological potential of PPM1G in hepatocellular carcinoma. (PMID:33952716)
• PPM1G promotes the progression of hepatocellular carcinoma via phosphorylation regulation of alternative splicing protein SRSF3. (PMID:34290239)
• High expression of PPM1G is associated with the progression and poor prognosis of hepatocellular carcinoma. (PMID:34366322)
• PPM1G promotes the progression of lung adenocarcinoma by inhibiting p38 activation via dephosphorylation of MEK6. (PMID:36349938)
• Prognostic and immunological potential of PPM1G in lung adenocarcinoma. (PMID:37387407)
• PPM1G promotes autophagy and progression of pancreatic cancer via upregulating HMGB1. (PMID:39121976)
• Functional study of the mouse homolog (PMID:9271424)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	ppm1g	ENSDARG00000075559
mus_musculus	Ppm1g	ENSMUSG00000029147
rattus_norvegicus	Ppm1g	ENSRNOG00000026905

Paralogs (16): PPM1F (ENSG00000100034), TAB1 (ENSG00000100324), PPM1A (ENSG00000100614), PPM1H (ENSG00000111110), ILKAP (ENSG00000132323), PPM1B (ENSG00000138032), PPM1J (ENSG00000155367), PPM1L (ENSG00000163590), PPM1K (ENSG00000163644), PPM1M (ENSG00000164088), PDP1 (ENSG00000164951), PPM1D (ENSG00000170836), PDP2 (ENSG00000172840), PPM1E (ENSG00000175175), PP2D1 (ENSG00000183977), PPM1N (ENSG00000213889)

Protein

Protein identifiers

Protein phosphatase 1G — O15355 (reviewed: O15355)

Alternative names: Protein phosphatase 1C, Protein phosphatase 2C isoform gamma, Protein phosphatase magnesium-dependent 1 gamma

All UniProt accessions (2): O15355, Q6IAU5

UniProt curated annotations — full annotation on UniProt →

Subunit / interactions. Interacts with NOL3; may dephosphorylate NOL3.

Subcellular location. Cytoplasm. Membrane.

Tissue specificity. Widely expressed. Most abundant in testis, skeletal muscle, and heart.

Cofactor. Binds 2 magnesium or manganese ions per subunit.

Similarity. Belongs to the PP2C family.

RefSeq proteins (1): NP_817092* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000222	PP2C_BS	Binding_site
IPR001932	PPM-type_phosphatase-like_dom	Domain
IPR015655	PP2C	Family
IPR036457	PPM-type-like_dom_sf	Homologous_superfamily

Pfam: PF00481

Catalyzed reactions (Rhea), 2 shown:

• O-phospho-L-seryl-[protein] + H2O = L-seryl-[protein] + phosphate (RHEA:20629)
• O-phospho-L-threonyl-[protein] + H2O = L-threonyl-[protein] + phosphate (RHEA:47004)

UniProt features (19 total): binding site 5, modified residue 5, region of interest 3, compositionally biased region 2, initiator methionine 1, chain 1, lipid moiety-binding region 1, domain 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-O15355-F1	73.42	0.52

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Ligand- & substrate-binding residues (5): 61; 441; 496; 60; 60

Post-translational modifications (6): 22, 122, 183, 383, 527, 2

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 184 (showing top): MORF_MTA1, MORF_DNMT1, MORF_ESPL1, YAGI_AML_WITH_INV_16_TRANSLOCATION, MORF_RRM1, MORF_HDAC1, MORF_UBE2N, MORF_HDAC2, WEI_MYCN_TARGETS_WITH_E_BOX, BROWNE_HCMV_INFECTION_24HR_UP, MORF_SKP1A, GOBP_REGULATION_OF_CELL_CYCLE, MORF_BUB3, MORF_RFC4, ATTCTTT_MIR186

GO Biological Process (4): protein dephosphorylation (GO:0006470), signal transduction (GO:0007165), peptidyl-threonine dephosphorylation (GO:0035970), regulation of cell cycle (GO:0051726)

GO Molecular Function (6): protein serine/threonine phosphatase activity (GO:0004722), metal ion binding (GO:0046872), phosphoprotein phosphatase activity (GO:0004721), protein binding (GO:0005515), hydrolase activity (GO:0016787), cation binding (GO:0043169)

GO Cellular Component (4): nucleus (GO:0005634), nucleoplasm (GO:0005654), cytoplasm (GO:0005737), membrane (GO:0016020)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	3
regulation of cellular process	2
dephosphorylation	1
protein modification process	1
cell communication	1
cellular process	1
signaling	1
cellular response to stimulus	1
protein dephosphorylation	1
cell cycle	1
phosphoprotein phosphatase activity	1
cation binding	1
phosphatase activity	1
catalytic activity, acting on a protein	1
binding	1
catalytic activity	1
ion binding	1
intracellular membrane-bounded organelle	1
nuclear lumen	1
intracellular anatomical structure	1

Protein interactions and networks

STRING

3482 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
PPM1G	HEXIM1	O94992	881
PPM1G	PPP1CC	P36873	686
PPM1G	PPP1CB	P37140	666
PPM1G	PPP1R12A	O14974	658
PPM1G	LARP7	Q4G0J3	655
PPM1G	MEPCE	Q7L2J0	634
PPM1G	PPM1M	Q96MI6	598
PPM1G	PPP5C	P53041	546
PPM1G	YBX1	P16990	533
PPM1G	THRAP3	Q9Y2W1	531
PPM1G	WWP2	O00308	529
PPM1G	PPP1R15B	Q5SWA1	516
PPM1G	PPP6C	O00743	511
PPM1G	H2BC21	Q16778	509
PPM1G	PPP1R15A	O75807	507

IntAct

198 interactions, top by confidence:

A	B	Type	Score
CDK8	MED19	psi-mi:“MI:2364”(proximity)	0.850
H2AX	PPM1G	psi-mi:“MI:0914”(association)	0.730
LRIF1	SMCHD1	psi-mi:“MI:0914”(association)	0.680
H2AC4	PPM1G	psi-mi:“MI:0914”(association)	0.670
PPM1G	XRCC6	psi-mi:“MI:0915”(physical association)	0.650
PPM1G	XRCC5	psi-mi:“MI:0915”(physical association)	0.650
H2BC1	PPM1G	psi-mi:“MI:0914”(association)	0.640
SRP14	PPM1G	psi-mi:“MI:0914”(association)	0.640
CHEK2	PPM1G	psi-mi:“MI:0914”(association)	0.560
PPM1G	CHEK2	psi-mi:“MI:0915”(physical association)	0.560
tat	PPM1G	psi-mi:“MI:0914”(association)	0.560
tat	PPM1G	psi-mi:“MI:0915”(physical association)	0.560
MTNR1B	IRS4	psi-mi:“MI:0914”(association)	0.530
CPA6	PPM1G	psi-mi:“MI:0914”(association)	0.530
MACROH2A2	PPM1G	psi-mi:“MI:0914”(association)	0.530
ZNF223	PPM1G	psi-mi:“MI:0914”(association)	0.530
PPM1G	COPE	psi-mi:“MI:0914”(association)	0.530

BioGRID (437): PPM1G (Two-hybrid), PPM1G (Affinity Capture-MS), PPM1G (Affinity Capture-MS), PPM1G (Affinity Capture-MS), PPM1G (Affinity Capture-MS), AHCYL1 (Co-fractionation), MED4 (Co-fractionation), PAIP1 (Co-fractionation), PPM1G (Co-fractionation), PPM1G (Co-fractionation), PPM1G (Co-fractionation), PPM1G (Co-fractionation), PPM1G (Co-fractionation), PPM1G (Co-fractionation), PPM1G (Co-fractionation)

ESM2 similar proteins: A0A7U2MSD6, F1LNI5, G0RT93, O15355, O80492, O81716, P34221, P36982, P39966, P40371, P49594, P49595, P49596, P79126, Q09172, Q09173, Q0IIF0, Q0J2R1, Q0JAA0, Q19775, Q29AP0, Q2R637, Q2RBJ6, Q4R4V2, Q4WTH5, Q61074, Q653S3, Q67J17, Q67UP9, Q6ETK3, Q6NKS1, Q6YTI2, Q6Z8B9, Q7XU84, Q8GY60, Q8H4S6, Q8LAY8, Q8R0F6, Q8RXZ4, Q94AT1

Diamond homologs: A0A7U2MSD6, A0BLX0, A0BQL0, A0CUB5, A0DSB3, A0DTY1, A3A8Q4, A3A8W2, A3A8W6, A5PJZ2, F1LNI5, G0RT93, O04719, O15355, O15743, O62829, O62830, O75688, O80871, O81716, P20650, P34221, P35813, P35814, P35815, P36993, P38089, P39966, P40371, P49443, P49444, P49593, P49595, P49596, P49597, P49598, P79126, P93006, Q09172, Q09173

SIGNOR signaling

7 interactions.

A	Effect	B	Mechanism
PPM1G	“up-regulates quantity by stabilization”	SNRPN	dephosphorylation
PPM1G	“down-regulates activity”	SRSF3	dephosphorylation
PPM1G	“up-regulates activity”	CDKN1B	dephosphorylation
PPM1G	“down-regulates activity”	ATM	dephosphorylation
PPM1G	“down-regulates activity”	USP7	dephosphorylation
ATM	“up-regulates activity”	PPM1G	phosphorylation
PPM1G	“down-regulates quantity by destabilization”	USP7	dephosphorylation

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 210 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Packaging Of Telomere Ends	13	18.7×	7e-11
Telomere Extension By Telomerase	6	17.9×	1e-05
Recognition and association of DNA glycosylase with site containing an affected purine	13	17.3×	7e-11
Cleavage of the damaged purine	13	17.3×	7e-11
Recognition and association of DNA glycosylase with site containing an affected pyrimidine	13	15.7×	2e-10
Cleavage of the damaged pyrimidine	13	15.7×	2e-10
DNA Damage/Telomere Stress Induced Senescence	14	14.9×	7e-11
Inhibition of DNA recombination at telomere	13	14.3×	5e-10

GO biological processes:

GO term	Partners	Fold	FDR
heterochromatin formation	9	12.4×	5e-05

Disease & clinical

Clinical variants and AI predictions

ClinVar

50 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	33
Likely benign	0
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

1665 predictions. Top by Δscore:

Variant	Effect	Δscore
2:27382121:CTCA:C	donor_loss	1.0000
2:27382122:TCA:T	donor_loss	1.0000
2:27382123:CA:C	donor_loss	1.0000
2:27382124:A:AC	donor_gain	1.0000
2:27382124:ACCTC:A	donor_loss	1.0000
2:27382125:C:A	donor_loss	1.0000
2:27382125:C:CC	donor_gain	1.0000
2:27382125:CCT:C	donor_gain	1.0000
2:27382224:CATTC:C	acceptor_gain	1.0000
2:27382226:TTC:T	acceptor_gain	1.0000
2:27382229:C:CA	acceptor_loss	1.0000
2:27382229:C:CC	acceptor_gain	1.0000
2:27382470:GCTCA:G	donor_loss	1.0000
2:27382471:CTCAC:C	donor_loss	1.0000
2:27382472:TCAC:T	donor_loss	1.0000
2:27382473:CA:C	donor_loss	1.0000
2:27382474:A:AC	donor_gain	1.0000
2:27382474:A:AG	donor_loss	1.0000
2:27382475:C:CC	donor_gain	1.0000
2:27382475:C:T	donor_loss	1.0000
2:27382601:GTCCC:G	acceptor_gain	1.0000
2:27382602:TCCC:T	acceptor_gain	1.0000
2:27382603:CCC:C	acceptor_gain	1.0000
2:27382603:CCCC:C	acceptor_gain	1.0000
2:27382604:CC:C	acceptor_gain	1.0000
2:27382604:CCC:C	acceptor_gain	1.0000
2:27382605:CC:C	acceptor_gain	1.0000
2:27382605:CCTGG:C	acceptor_loss	1.0000
2:27382606:C:CC	acceptor_gain	1.0000
2:27382606:C:T	acceptor_gain	1.0000

AlphaMissense

3616 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
2:27381740:G:C	C500W	1.000
2:27381742:A:G	C500R	1.000
2:27381749:G:C	N497K	1.000
2:27381749:G:T	N497K	1.000
2:27381750:T:A	N497I	1.000
2:27381751:T:C	N497D	1.000
2:27381752:G:C	D496E	1.000
2:27381752:G:T	D496E	1.000
2:27381753:T:A	D496V	1.000
2:27381753:T:C	D496G	1.000
2:27381753:T:G	D496A	1.000
2:27381754:C:A	D496Y	1.000
2:27381754:C:G	D496H	1.000
2:27381756:C:T	C495Y	1.000
2:27381759:C:A	G494V	1.000
2:27381759:C:T	G494E	1.000
2:27381760:C:A	G494W	1.000
2:27381760:C:G	G494R	1.000
2:27381760:C:T	G494R	1.000
2:27381765:C:A	G492V	1.000
2:27381765:C:T	G492D	1.000
2:27381766:C:G	G492R	1.000
2:27381791:G:C	C483W	1.000
2:27381793:A:G	C483R	1.000
2:27381804:A:G	L479P	1.000
2:27382213:G:C	S449R	1.000
2:27382213:G:T	S449R	1.000
2:27382215:T:G	S449R	1.000
2:27382225:A:C	N445K	1.000
2:27382225:A:T	N445K	1.000

dbSNP variants (sampled 300 via entrez): RS1000086753 (2:27398868 G>T), RS1000116319 (2:27399143 C>A), RS1000279333 (2:27386128 C>T), RS1000344477 (2:27393236 G>A,C,T), RS1000534757 (2:27397556 C>A), RS1000563626 (2:27402284 A>T), RS1000673954 (2:27393006 A>G), RS1000788341 (2:27407929 C>A), RS1000881466 (2:27384277 T>G), RS1000926099 (2:27390749 C>T), RS1001019525 (2:27390512 G>C), RS1001088439 (2:27397461 A>G), RS1001268596 (2:27410617 T>C,G), RS1001461781 (2:27404794 A>T), RS1001529601 (2:27401195 G>T)

Disease associations

OMIM: gene MIM:605119 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

8 associations (top):

Study	Trait	p-value
GCST001905_4	Hypertriglyceridemia	2.000000e-13
GCST004131_72	Inflammatory bowel disease	1.000000e-07
GCST004132_64	Crohn’s disease	6.000000e-11
GCST006143_9	Bone mineral density (total hip)	5.000000e-06
GCST006575_57	Takayasu arteritis	8.000000e-06
GCST007877_1	Creatinine levels	2.000000e-12
GCST010134_1	Non-oily fish consumption	9.000000e-09
GCST010660_9	Triglyceride levels	1.000000e-25

EFO canonical traits (3, from GWAS)

EFO ID	Trait name
EFO:0004530	triglyceride measurement
EFO:0007702	hip bone mineral density
EFO:0008111	diet measurement

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL3351199 (SINGLE PROTEIN)

Molecules with ChEMBL bioactivity

1 molecules (phase ≥1), by development phase (incl. off-target/promiscuous compounds). Patent mentions across the top 20 by phase: 1,538 (via chembl_molecule»patent_compound — counts attach to the compound, not the gene–compound relationship, so off-target/promiscuous molecules can dominate).

Molecule	Name	Phase	Patents
CHEMBL1232461	MOLIBRESIB	2	1,538

PharmGKB: 1 entry (VIP=true, CPIC=false)

ChEMBL bioactivities

3 potent at pChembl≥5 of 7 total, top 3 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
7.30	IC50	50	nM	MOLIBRESIB
6.36	Kd	441.6	nM	CHEMBL3752910
6.36	ED50	441.6	nM	CHEMBL3752910

PubChem BioAssay actives

2 with measured affinity, of 21 total; 2 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
2-[(4S)-6-(4-chlorophenyl)-8-methoxy-1-methyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepin-4-yl]-N-ethylacetamide	2178544: Inhibition of PPM1G (unknown origin) incubated for 1 hr by colloidal coomassie staining based LC-MS/MS analysis	ic50	0.0500	uM
4-methyl-3-[(1-methyl-6-pyridin-3-ylpyrazolo[3,4-d]pyrimidin-4-yl)amino]-N-[3-(trifluoromethyl)phenyl]benzamide	2149047: Binding affinity to human PPM1G incubated for 45 mins by Kinobead based pull down assay	kd	0.4416	uM

CTD chemical–gene interactions

39 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects expression, increases expression	3
bisphenol A	decreases expression	2
sodium arsenite	decreases expression, increases expression	2
perfluorooctanoic acid	decreases expression	2
Tretinoin	increases reaction, decreases expression	2
aristolochic acid I	increases expression	1
FR900359	affects phosphorylation	1
titanium dioxide	increases expression	1
mono-(2-ethylhexyl)phthalate	decreases methylation, increases abundance	1
zinc chromate	decreases expression, increases abundance	1
ochratoxin A	increases expression	1
beta-methylcholine	affects expression	1
di-n-butylphosphoric acid	affects expression	1
chromium hexavalent ion	decreases expression, increases abundance	1
perfluorooctane sulfonic acid	decreases expression	1
perfluoro-n-nonanoic acid	decreases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, decreases expression	1
perfluorohexanesulfonic acid	decreases expression	1
bisphenol B	increases expression	1
2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine	decreases expression, increases response to substance	1
LDN 193189	affects cotreatment, decreases expression	1
Oxaliplatin	increases expression	1
Rosiglitazone	increases expression	1
Arsenic	affects methylation	1
Atrazine	increases expression	1
Benzo(a)pyrene	affects methylation	1
Carbamazepine	affects expression	1
Carmustine	decreases expression	1
Diethylhexyl Phthalate	decreases methylation, increases abundance	1
Enzyme Inhibitors	decreases activity, increases O-linked glycosylation	1

ChEMBL screening assays

13 unique, capped per target: 13 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL3386721	Binding	Inhibition of PPM1G (unknown origin) assessed as reduction in pNPP hydrolysis	Fast identification of novel lymphoid tyrosine phosphatase inhibitors using target-ligand interaction-based virtual screening. — J Med Chem

Cellosaurus cell lines

2 cell lines: 1 transformed cell line, 1 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_B3EH	Abcam HEK293T PPM1G KO	Transformed cell line	Female
CVCL_TF42	HAP1 PPM1G (-)	Cancer cell line	Male

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.